Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.
Asaf Danziger, insider at NovoCure

Asaf Danziger Insider Information

CEO of NovoCure
Asaf Danziger has served as Chief Executive Officer of Novocure since 2002 and has been a director of Novocure since 2012.  Mr. Danziger has led the company and the development of TTFields therapy from preclinical testing through regulatory approvals to commercial sales in Europe and the United States.  From 1998 to 2002, Mr. Danziger was Chief Executive Officer of Cybro Medical, a subsidiary of Imagyn Medical Technologies.  Mr. Danziger holds a B.Sc. in material engineering from Ben Gurion University of the Negev, Israel.

What is Asaf Danziger's net worth?

The estimated net worth of Asaf Danziger is at least $22.53 million as of December 18th, 2020. Mr. Danziger owns 301,587 shares of NovoCure stock worth more than $22,528,549 as of May 22nd. This net worth evaluation does not reflect any other assets that Mr. Danziger may own. Additionally, Mr. Danziger receives a salary of $2,010,000.00 as CEO at NovoCure. Learn More about Asaf Danziger's net worth.

How old is Asaf Danziger?

Mr. Danziger is currently 56 years old. There are 7 older executives and no younger executives at NovoCure. Learn More on Asaf Danziger's age.

What is Asaf Danziger's salary?

As the CEO of NovoCure Limited, Mr. Danziger earned a total compensation package of $8,956,704.00 in 2020. Mr. Danziger earned a salary of $781,868.00, stock awards of $6,946,850.00, non-equity compensation of $934,607.00, and other compensation of $293,379.00. Learn More on Asaf Danziger's salary.

How do I contact Asaf Danziger?

The corporate mailing address for Mr. Danziger and other NovoCure executives is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. NovoCure can also be reached via phone at 441534756700 and via email at [email protected] Learn More on Asaf Danziger's contact information.

Has Asaf Danziger been buying or selling shares of NovoCure?

Asaf Danziger has not been actively trading shares of NovoCure within the last three months. 0 shares of the stock in a transaction dated Sunday, May 22nd. Learn More on Asaf Danziger's trading history.

Who are NovoCure's active insiders?

NovoCure's insider roster includes Michael Ambrogi (COO), Ely Benaim (Insider), Ashley Cordova (CFO), Asaf Danziger (CEO), William Doyle (Chairman), Wilhelmus Groenhuysen (COO), Jeryl Hilleman (Director), Frank Leonard (Insider), Gabriel Leung (Director), Todd Longsworth (General Counsel), Martin Madden (Director), Pritesh Shah (Insider), and Uri Weinberg (Insider). Learn More on NovoCure's active insiders.

Are insiders buying or selling shares of NovoCure?

During the last twelve months, NovoCure insiders bought shares 1 times. They purchased a total of 4,974 shares worth more than $509,536.56. During the last twelve months, insiders at the medical equipment provider sold shares 22 times. They sold a total of 80,673 shares worth more than $11,829,808.03. The most recent insider tranaction occured on March, 9th when insider Pritesh Shah sold 3,669 shares worth more than $261,196.11. Insiders at NovoCure own 5.1 % of the company. Learn More about insider trades at NovoCure.

Information on this page was last updated on 3/9/2022.

Asaf Danziger Insider Trading History at NovoCure

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/26/2021Buy4,974$102.44$509,536.56View SEC Filing Icon  
4/13/2021Sell97,973$196.34$19,236,018.82View SEC Filing Icon  
12/18/2020Sell207,910$157.39$32,722,954.90301,587View SEC Filing Icon  
11/25/2019Sell103,000$95.00$9,785,000.00237,601View SEC Filing Icon  
8/29/2019Sell124,181$91.13$11,316,614.53200,869View SEC Filing Icon  
6/28/2019Sell187,500$62.15$11,653,125.00445,811View SEC Filing Icon  
6/18/2019Sell190,338$59.37$11,300,367.06448,649View SEC Filing Icon  
6/12/2019Sell30,436$55.39$1,685,850.04275,146View SEC Filing Icon  
3/4/2019Sell16,268$55.89$909,218.52250,025View SEC Filing Icon  
2/28/2019Sell903$54.40$49,123.20233,757View SEC Filing Icon  
2/13/2019Sell50,000$51.46$2,573,000.00View SEC Filing Icon  
1/23/2019Sell88,695$47.48$4,211,238.60259,859View SEC Filing Icon  
1/17/2019Sell100,000$45.26$4,526,000.00271,164View SEC Filing Icon  
1/15/2019Sell200,000$43.51$8,702,000.00271,164View SEC Filing Icon  
6/27/2018Sell70,364$32.09$2,257,980.7669,318View SEC Filing Icon  
6/20/2018Sell8,308$32.04$266,188.32147,990View SEC Filing Icon  
6/18/2018Sell22,289$32.00$713,248.00147,990View SEC Filing Icon  
6/14/2018Sell11,920$32.00$381,440.00171,100View SEC Filing Icon  
6/4/2018Sell227,304$29.09$6,612,273.36260,246View SEC Filing Icon  
1/29/2018Sell13,974$24.02$335,655.48356,790View SEC Filing Icon  
1/24/2018Sell20,848$22.10$460,740.80387,820View SEC Filing Icon  
1/16/2018Sell14,900$22.20$330,780.00398,068View SEC Filing Icon  
1/12/2018Sell336,420$22.33$7,512,258.60435,863View SEC Filing Icon  
11/6/2017Sell6,919$22.00$152,218.00View SEC Filing Icon  
11/3/2017Sell2,300$22.00$50,600.00756,024View SEC Filing Icon  
11/1/2017Sell15,866$22.01$349,210.66774,040View SEC Filing Icon  
9/25/2017Sell900$22.05$19,845.00774,190View SEC Filing Icon  
9/14/2017Sell37,272$22.01$820,356.72776,862View SEC Filing Icon  
9/13/2017Sell35,500$22.01$781,355.00776,862View SEC Filing Icon  
7/11/2017Sell7,383$19.95$147,290.85462,765View SEC Filing Icon  
7/10/2017Sell274,359$18.07$4,957,667.13668,865View SEC Filing Icon  
7/6/2017Sell160,138$18.14$2,904,903.32899,462View SEC Filing Icon  
7/5/2017Sell155,088$18.14$2,813,296.32899,462View SEC Filing Icon  
6/19/2017Sell124,720$15.51$1,934,407.20896,917View SEC Filing Icon  
6/16/2017Sell42,457$15.15$643,223.551,030,849View SEC Filing Icon  
6/14/2017Sell94,102$15.22$1,432,232.441,069,496View SEC Filing Icon  
6/12/2017Sell180,601$15.13$2,732,493.131,163,296View SEC Filing Icon  
3/3/2016Buy10,000$15.00$150,000.00933,557View SEC Filing Icon  
See Full Table

Asaf Danziger Buying and Selling Activity at NovoCure

This chart shows Asaf Danziger's buying and selling at NovoCure by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

NovoCure Company Overview

NovoCure logo
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma. The company markets its products in the European Union, the United Kingdom, Japan, and internationally. It has a clinical study collaboration agreement with MSD to study TTFields together with KEYNOTE, an anti-PD-1 therapy; and a strategic collaboration with Zai Lab (Shanghai) Co., Ltd. to commercialize its products in Greater China and establishes a development partnership intended to accelerate the development of TTFields in multiple solid tumor cancer indications. NovoCure Limited was incorporated in 2000 and is based in Saint Helier, Jersey.
Read More

Today's Range

Now: $74.70
Low: $70.32
High: $76.98

50 Day Range

MA: $78.39
Low: $57.94
High: $89.90

2 Week Range

Now: $74.70
Low: $56.51
High: $232.76

Volume

589,775 shs

Average Volume

639,019 shs

Market Capitalization

$7.81 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88
How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
Click here now to join and get access to our forecasting.